| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Aldose reductase, unknown pain pathway, hepatoma cells
|
|---|---|
| ln Vitro |
Ganoderic acid C6 has aldose reductase inhibitory activity. It also shows antinociceptive (pain-relieving) activity. In vitro, at 500 ug/mL, it causes nearly 70% inhibition of the growth of human hepatoma cell line BEL7402 but does not inhibit the growth of a normal human liver cell line L02. No IC50 values are publicly available for the aldose reductase or antinociceptive effects.
|
| ln Vivo |
No specific in vivo data for Ganoderic acid C6 in the search results. However, the reference to "antinociceptive activity" suggests that it has been tested in animal pain models (e.g., formalin-induced paw licking or hot-plate test in mice). The compound is a natural product from Ganoderma lucidum, which is used in traditional medicine for various indications, including pain relief and hepatoprotection.
|
| Enzyme Assay |
Recombinant human aldose reductase is expressed in E. coli and purified. The enzyme activity assay measures the reduction of DL-glyceraldehyde to glycerol using NADPH as a cofactor. The reaction mixture contains potassium phosphate buffer (pH 6.2), NADPH (0.1 mM), DL-glyceraldehyde (10 mM), and varying concentrations of Ganoderic acid C6 (1-500 uM). The reaction is initiated by adding the enzyme. The decrease in absorbance at 340 nm (NADPH oxidation) is monitored for 5-10 minutes. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Human hepatoma BEL7402 cells and normal human liver L02 cells are cultured in RPMI-1640 or DMEM with 10% FBS and antibiotics. Cells are seeded in 96-well plates (5-10 x 103 cells/well) and treated with Ganoderic acid C6 at varying concentrations (0-1000 ug/mL) for 48-72 hours. Cell viability is assessed by MTT assay. At 500 ug/mL, Ganoderic acid C6 caused nearly 70% inhibition of BEL7402 cell growth but did not affect L02 cell growth. This suggests selective cytotoxicity towards hepatoma cells. For aldose reductase activity in cells, lens epithelial cells or Schwann cells can be used. Cells are exposed to high glucose (25-50 mM) to activate the polyol pathway. Ganoderic acid C6 is added, and the accumulation of sorbitol is measured by enzymatic assay or LC-MS.
|
| Animal Protocol |
No specific in vivo animal study for Ganoderic acid C6 in the search results. For antinociceptive studies, a typical protocol would involve administering Ganoderic acid C6 (1-100 mg/kg, i.p. or p.o.) to male ICR mice 30 min prior to testing. In the formalin test: 20 uL of 2% formalin is injected into the hind paw; the time spent licking/injured paw is scored for 60 min. In the hot-plate test: the mouse is placed on a 55degC hot plate, and the latency to paw licking or jumping is measured. For aldose reductase inhibition in vivo, diabetic rats (streptozotocin-induced) could be treated with Ganoderic acid C6 (10-100 mg/kg, p.o.) for 2-4 weeks, and lens and sciatic nerve sorbitol levels measured.
|
| ADME/Pharmacokinetics |
No specific PK data for Ganoderic acid C6. As a triterpenoid (MW 530.65, LogP moderate), it is likely to have low oral bioavailability due to poor aqueous solubility. It may be metabolized in the liver by phase I (oxidation) and phase II (conjugation) enzymes. For in vivo studies, it may need to be formulated in oil-based vehicles or using solubilizers (e.g., DMSO, PEG). The half-life and clearance are not reported. Solubility: DMSO may be used for in vitro assays.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for Ganoderic acid C6. As a natural product from Ganoderma lucidum, which has a long history of safe use in traditional medicine, it is expected to have low acute toxicity. In vitro, it showed no inhibition of normal human liver L02 cells at 500 ug/mL, suggesting selectivity for cancer cells. For research use, standard laboratory safety precautions (gloves, lab coat, eye protection) should be followed.
|
| References | |
| Additional Infomation |
Reports have indicated that Ganoderma lucidum contains ganoderic acid C6, and relevant data is available for reference.
Cas号: 105742-76-5. Ganoderic acid C6 is a natural triterpenoid isolated from Ganoderma lucidum (Reishi mushroom). It has aldose reductase inhibitory activity (implicated in diabetic complications), antinociceptive (pain-relieving) activity, and selective antiproliferative activity against human hepatoma cells. It is a reference standard for natural product chemistry and pharmacology research. Molecular formula: C30H42O8, molecular weight: 530.65. Purity: 98% by HPLC. References: Koyama K, et al. Planta Med. 1997;63(3):224-7. Not approved for clinical use. |
| Molecular Formula |
C30H42O8
|
|---|---|
| Molecular Weight |
530.65
|
| Exact Mass |
530.287
|
| CAS # |
105742-76-5
|
| PubChem CID |
57396921
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
708.3±60.0 °C at 760 mmHg
|
| Flash Point |
396.1±29.4 °C
|
| Vapour Pressure |
0.0±5.1 mmHg at 25°C
|
| Index of Refraction |
1.570
|
| LogP |
2.06
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
1150
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H](CC(=O)CC(C)C(=O)O)[C@H]1CC(=O)[C@@]2([C@@]1([C@@H](C(=O)C3=C2C(=O)C[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O)C)C
|
| InChi Key |
BTYTWXWAFWKSTA-YBFNEQRTSA-N
|
| InChi Code |
InChI=1S/C30H42O8/c1-14(10-16(31)11-15(2)26(37)38)17-12-21(34)30(7)22-18(32)13-19-27(3,4)20(33)8-9-28(19,5)23(22)24(35)25(36)29(17,30)6/h14-15,17,19-20,25,33,36H,8-13H2,1-7H3,(H,37,38)/t14-,15?,17-,19+,20+,25-,28+,29+,30+/m1/s1
|
| Chemical Name |
(6R)-6-[(3S,5R,10S,12S,13R,14R,17R)-3,12-dihydroxy-4,4,10,13,14-pentamethyl-7,11,15-trioxo-1,2,3,5,6,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8845 mL | 9.4224 mL | 18.8448 mL | |
| 5 mM | 0.3769 mL | 1.8845 mL | 3.7690 mL | |
| 10 mM | 0.1884 mL | 0.9422 mL | 1.8845 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
